Safety of buprenorphine transdermal system in the management of pain in older adults

被引:14
|
作者
Pergolizzi, Joseph V. [1 ,2 ]
Raffa, Robert B. [3 ,4 ]
Marcum, Zachary [5 ]
Colucci, Salvatore [6 ]
Ripa, Steven R. [6 ]
机构
[1] Naples Anesthesia & Pain Associates, Naples, FL USA
[2] NEMA Res Inc, Naples, FL USA
[3] Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19122 USA
[4] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA
[5] Univ Washington, Sch Pharm, Seattle, WA 98195 USA
[6] Purdue Pharma LP, One Stamford Forum, Stamford, CT 06901 USA
关键词
Buprenorphine; BTDS; pain management in older adults; elderly; controlled and uncontrolled trials; 7-day transdermal formulation; geriatric pain medicine; opioid; LOW-BACK-PAIN; DOUBLE-BLIND; OPIOID ANALGESIA; ELDERLY-PATIENTS; MEDICATION USE; RISK; FALLS; FRACTURES; OSTEOARTHRITIS; MODERATE;
D O I
10.1080/00325481.2017.1270699
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To evaluate whether buprenorphine transdermal system (BTDS; Butrans (R)) is an option for the treatment of chronic pain in older adults. Methods: This retrospective analysis of 16 placebo- and active-controlled and uncontrolled studies (N = 6566) evaluated the safety and tolerability profile in patients exposed to BTDS and compared the safety profiles associated with BTDS treatment in older patients = 65 years of age (65 to 98 years) and younger patients < 65 years of age (18 to 64 years). Safety analyses included adverse events (AEs), laboratory values, and electrocardiograms. Results: Overall, the incidence of AEs was similar in the = 65 year patient cohort (N = 1715) and the < 65 year patient cohort (N = 4843) (63.8% and 61.0%, respectively). The older patient cohort experienced more constipation, peripheral edema, and urinary tract infection, but fewer application-site AEs (eg, erythema, irritation, pruritus, rash) and headaches. A statistically significant treatment-by-age interaction was observed for fall, arthralgia, and localized and non-application site-related rash, suggesting a differential increase in the risk of these events among older patients treated with BTDS that cannot be explained by age or treatment alone. A similar trend was observed for accidents and injuries, and for falls, in patients treated with both BTDS and active controls (oxycodone/acetaminophen [OXY/APAP] and hydrocodone/acetaminophen [HCD/APAP]), suggesting an opioid class effect. However, due to small sample sizes of the active control groups, a statistical test of treatment-by-age interaction could not be conducted for the active controls. The incidences of serious AEs and of clinically significant increases in liver enzymes, such as AST, ALT and bilirubin were small, regardless of age. Conclusion: BTDS appears to be a viable option for the management of pain in older adults, but the benefits need to be tempered by potential risks among older adults.
引用
收藏
页码:92 / 101
页数:10
相关论文
共 50 条
  • [31] Buprenorphine in a transdermal therapeutic system -: A new option
    Böhme, K
    CLINICAL RHEUMATOLOGY, 2002, 21 (Suppl 1) : S13 - S16
  • [32] Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain
    Yarlas, Aaron
    Miller, Kate
    Wen, Warren
    Lynch, Shau Yu
    Munera, Catherine
    Pergolizzi, Joseph V., Jr.
    Raffa, Robert
    Ripa, Steven R.
    POSTGRADUATE MEDICINE, 2015, 127 (01) : 38 - 45
  • [33] Efficacy of Transdermal Buprenorphine Patch in Postoperative Pain Management in Oral and Maxillofacial Surgery
    Mythili, N.
    Navaneetham, Romir
    Sham, M. E.
    Menon, Suresh
    Kumar, Veerendra
    Archana, S.
    JOURNAL OF MAXILLOFACIAL & ORAL SURGERY, 2024, 23 (05): : 1234 - 1239
  • [34] Effectiveness and safety of transdermal buprenorphine for chronic pain treatment in the elderly: a prospective observational study
    Muriel Villoria, Clemente
    Perez-Castejon Garrote, Juan Manuel
    Sanchez Magro, Isabel
    Neira Alvarez, Marta
    MEDICINA CLINICA, 2007, 128 (06): : 204 - 210
  • [35] Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system
    Silverman, Sanford
    Raffa, Robert B.
    Cataldo, Marc J.
    Kwarcinski, Monica
    Ripa, Steven R.
    JOURNAL OF PAIN RESEARCH, 2017, 10 : 1255 - 1263
  • [36] Pain Therapeutics in Older Adults
    Boockvar, Kenneth
    CLINICAL THERAPEUTICS, 2013, 35 (11) : 1656 - 1658
  • [37] PAIN MANAGEMENT IN PALLIATIVE CANCER PATIENTS: A PROSPECTIVE OBSERVATIONAL STUDY ON THE USE OF HIGH DOSAGES OF TRANSDERMAL BUPRENORPHINE
    Clement, P. M. J.
    Beuselinck, B.
    Mertens, P. G.
    Cornelissen, N.
    Menten, J.
    ACTA CLINICA BELGICA, 2013, 68 (02) : 87 - 91
  • [38] The Impact of Buprenorphine Transdermal Delivery System on Activities of Daily Living Among Patients With Chronic Low Back Pain An Application of the International Classification of Functioning, Disability and Health
    Miller, Kate
    Yarlas, Aaron
    Wen, Warren
    Dain, Bradley
    Lynch, Shau Yu
    Ripa, Steven R.
    Pergolizzi, Joseph V., Jr.
    Raffa, Robert
    CLINICAL JOURNAL OF PAIN, 2014, 30 (12): : 1015 - 1022
  • [39] Efficacy and safety of Z-substances in the management of insomnia in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing
    Scharner, Vincenz
    Hasieber, Lukas
    Sonnichsen, Andreas
    Mann, Eva
    BMC GERIATRICS, 2022, 22 (01)
  • [40] Chronic Pain Management in Older Adults: Special Considerations
    Fine, Perry G.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2009, 38 (02) : S4 - S14